...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Alimentary pharmacology & therapeutics. >Increased risk of developing Crohn’s disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease
【24h】

Increased risk of developing Crohn’s disease or ulcerative colitis in 17?018 patients while under treatment with anti‐TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease

机译：在17岁患者中提高克罗恩病或溃疡性结肠炎的风险增加，同时用抗TNFα剂，特别是entanErcept治疗，特别是炎症性肠病以外的自身免疫疾病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary Background Anti‐TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. Aim To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with anti‐TNFα agents for diseases other than inflammatory bowel disease (IBD) Methods A nationwide cohort study, based on Danish health registries, of all patients who utilised anti‐TNFα agents for non‐IBD indications. Included were patients, who had diseases for which anti‐TNFα agent is indicated (rheumatoid arthritis, psoriasis/psoriatic arthritis, ankylosing spondylitis, others). The observation period for development of de novo IBD started from 2004. Exposed patients had received at least one dose of anti‐TNFα. Results In total 17?018 individuals with autoimmune diseases were exposed to anti‐TNFα (the vast majority had infliximab, etanercept and adalimumab), and 63?308 individuals were not. Patients treated with etanercept had an increased risk of being diagnosed with CD and UC while under treatment, adjusted hazard ratio 2.0 [95% CI: 1.4‐2.8] and 2.0 [95% CI: 1.5‐2.8], respectively. The corresponding hazards ratios for infliximab were 1.3 [95% CI: 0.8‐2.2] and 1.0 [95% CI:0.6‐1.6], and for adalimumab 1.2 [95% CI: 0.8‐1.8] and 0.6 [95% CI: 0.3‐1.0]. Conclusions Patients treated for autoimmune diseases with anti‐TNFα had an increased risk of being diagnosed with CD or UC while under treatment with etanercept. The nature of this association is uncertain. This finding has relevance to clinical care and insights into common mechanisms of the pathophysiology of these diseases.
机译：发明内容背景抗TNFα代理具有革命性的慢性炎症疾病的管理。矛盾的是，这些药剂可能会引发De Novo自身免疫疾病的发育。目的探讨在抗炎肠病（IBD）方法除丹麦健康的全国范围内的疾病治疗时，探讨是否存在发育克罗恩疾病（CD）和溃疡性结肠炎（UC）的风险。注册管理机构，用于用于非IBD适应症的抗TNFα代理的所有患者。包括患者，患有抗TNFα剂的疾病（类风湿性关节炎，牛皮癣/银屑病性关节炎，带状肌脊柱炎，其他）。从2004年开始开发De Novo IBD的观察期。暴露的患者至少接受了至少一种剂量的抗TNFα。结果总计17种患有自身免疫性疾病的18个，暴露于抗TNFα（绝大多数有英夫利昔单抗，依托普齐和Adalimumab），63个？308个人不是。用乙酸乙醚治疗的患者在治疗过程中被诊断为CD和UC的风险增加，调整后的危险比2.0 [95％CI：1.4-2.8]和2.0 [95％CI：1.5-2.8]。英夫利昔单抗的相应危险比为1.3 [95％CI：0.8-2.2]和1.0 [95％CI：0.6-1.6]，并且对于Adalimalab1.2 [95％Ci：0.8-1.8]和0.6 [95％Ci：0.3] -1.0]。结论用于抗TNFα的自身免疫疾病治疗的患者的风险增加，患有CD或UC的风险增加，同时在用依赖替科普治疗。这种协会的性质是不确定的。这一发现与临床护理和洞察中的临床护理和洞察有关这些疾病病理生理学的共同机制。

著录项

  • 来源
  • 作者

    Korzenik Joshua; Larsen Michael Due; Nielsen Jan; Kjeldsen Jens; N?rg?rd Bente Mertz;

  • 作者单位

    Division of Gastroenterology Hepatology and Endoscopy Department of MedicineBrigham and Women’s;

    Center for Clinical EpidemiologyOdense University HospitalOdense Denmark;

    Center for Clinical EpidemiologyOdense University HospitalOdense Denmark;

    Department of Medical Gastroenterology SOdense University HospitalOdense Denmark;

    Division of Gastroenterology Hepatology and Endoscopy Department of MedicineBrigham and Women’s;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号